A randomised trial of Daratumumab to remove myeloma cells from blood stem cells before an autograft for patients with multiple myeloma
- Registry ID
- EUCTR2019-002147-20
- Source registry
- EUCTR
- Status
- GB - no longer in EU/EEA
- Phase
- PHASE3
- Sponsor
- University of Birmingham
- Start date
- 2020-10-09
- Last update
- 2026-08-16
Conditions
- Newly diagnosed Multiple Myeloma (MM)
Summary
The principle objective is to determine the percentage of patients achieving minimal residual disease (MRD) negativity on bone marrow (BM) at day 100 post-transplant.
Locations
View on source registry